REGN ALERT: Securities Fraud Class Action Launched Against Regeneron Pharmaceuticals, Inc. - September 14, 2026 Deadline
Levi & Korsinsky announced a class action lawsuit against Regeneron Pharmaceuticals alleging securities fraud related to its Fianlimab-Libtayo Phase III study. The complaint claims Regeneron made misleading statements about the trial's statistical assumptions and clinical differentiation, leading to alleged stock drops of 6.2% and 9.8% in April and May 2026.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.